Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context

Abstract Onset‐predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years. OPBT results could be used as inclusion criterion for clinical trials for FTD, but this requires disclosure of OPBT results to potential participants for informed co...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte H. Graafland, Laura Donker Kaat, Edo Richard, John C. vanSwieten, Harro Seelaar, Eline M. Bunnik
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
biomarker
clinical trial
disclosure
ethics
frontotemporal dementia
informed consent
Online Access:https://doi.org/10.1002/dad2.70133
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items